List of Excipients in Branded Drug DUVYZAT

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Italfarmaco SPA	DUVYZAT	givinostat	11797-110	COW MILK FAT	2031-03-21
Italfarmaco SPA	DUVYZAT	givinostat	11797-110	GLYCERIN	2031-03-21
Italfarmaco SPA	DUVYZAT	givinostat	11797-110	NONCRYSTALLIZING SORBITOL SOLUTION	2031-03-21
Italfarmaco SPA	DUVYZAT	givinostat	11797-110	PEACH	2031-03-21
Italfarmaco SPA	DUVYZAT	givinostat	11797-110	POLYSORBATE 20	2031-03-21

Duvyzat Excipient Strategy and Commercial Opportunities in Givinostat Oral Suspension

Last updated: September 24, 2026

Duvyzat (givinostat) is an FDA-approved oral suspension for Duchenne muscular dystrophy (DMD) in patients aged 6 years and older. Its excipient strategy is commercially important because the product must deliver weight-based dosing, support chronic pediatric use, remain physically and chemically stable as a suspension, and provide a palatable alternative to tablets or capsules. The strongest opportunities are in pediatric taste masking, low-sedimentation suspension systems, dosing-device integration, preservative optimization, and global reformulation.

What is Duvyzat and which dosage form does it use?

Duvyzat contains givinostat, a histone deacetylase inhibitor developed by Italfarmaco. The FDA approved the product on March 21, 2024, for DMD patients aged 6 years and older, including patients receiving corticosteroids [1].

Duvyzat is supplied as an oral suspension with a concentration of 8.86 mg/mL. The formulation supports weight-based dosing:

Patient weight	Recommended dose
Less than 40 kg	6 mg/kg twice daily
40 kg or more	5 mg/kg twice daily
Maximum	100 mg twice daily

The product is administered using an oral syringe. The liquid format avoids swallowing barriers that affect younger DMD patients and permits dose adjustment as body weight changes.

The FDA label identifies the product as an oral suspension rather than a solution, indicating that formulation performance depends on particle wetting, dispersion, sedimentation control, redispersibility, and dose uniformity [2].

What excipients are used in Duvyzat oral suspension?

The commercial formulation uses excipients that address four core requirements: suspension stability, palatability, microbiological protection, and accurate dose delivery.

Public labeling identifies excipient categories including a viscosity-building polymer, glycerin, sodium benzoate, sucralose, citrate buffering agents, flavoring, and purified water [2]. The formulation is designed for repeated oral administration in a pediatric population and is supplied as a ready-to-use liquid rather than a powder requiring reconstitution.

Excipient function	Likely formulation role in Duvyzat
Suspending or thickening polymer	Limits sedimentation and supports dose uniformity
Glycerin	Humectant, viscosity modifier, and mouthfeel agent
Sodium benzoate	Antimicrobial preservative
Sucralose	High-intensity sweetener for taste masking
Citrate system	pH control and formulation stability
Flavor	Reduction of bitterness and metallic aftertaste
Purified water	Continuous vehicle

The excipient system is commercially relevant because givinostat is a potent small molecule administered chronically at relatively low liquid volumes. The formulation must prevent underdosing at the top of the bottle, maintain acceptable taste over repeated use, and remain compatible with the supplied oral syringe.

Why is givinostat difficult to formulate?

Givinostat has a pharmacologically active dose that is small relative to the volume of suspension vehicle. This creates a dose-uniformity challenge. If particles settle rapidly or form a compact sediment, the first and last doses may not contain equivalent amounts of active ingredient.

A pediatric suspension also must manage:

• Bitter or unpleasant active-ingredient taste
• Mouthfeel caused by polymers and suspended particles
• Potential adsorption to plastic dosing syringes
• Preservative compatibility
• Microbial growth during repeated bottle opening
• Viscosity changes during storage
• Redispersion after standing
• Accurate measurement across multiple syringe sizes

The formulation therefore has greater technical complexity than a conventional flavored oral solution.

What formulation patents protect Duvyzat?

Duvyzat is protected by a combination of drug-substance, therapeutic-use, formulation, and regulatory exclusivity rights. The commercial product is based on givinostat, while Italfarmaco and related entities have developed patent protection around the compound and its use in muscular dystrophy.

Public patent records associated with givinostat include earlier compound and use patents. Patent coverage may differ by jurisdiction and by patent family, and the presence of a patent does not establish that every claim covers the marketed Duvyzat suspension.

Protection category	Relevance to Duvyzat
Givinostat compound claims	Protect the active pharmaceutical ingredient
DMD treatment claims	Protect use in Duchenne muscular dystrophy
Dose-regimen claims	May cover weight-based or repeated administration
Oral suspension claims	May cover concentration, excipient system, or physical properties
Manufacturing claims	May restrict preparation of givinostat or formulated product
Regulatory exclusivity	Limits approval of competing applications independently of patent scope

The FDA-approved label and Orange Book remain the primary sources for determining listed patents, expiration dates, and any use codes for the marketed product [2, 3]. The label alone does not establish the full global patent estate.

Does Duvyzat have an excipient-specific patent moat?

The commercial protection of an excipient system depends on claim breadth. A narrow claim directed to a particular polymer, preservative level, pH range, or sedimentation profile may be vulnerable to design-around. A broader claim covering the active ingredient in a stable oral suspension with defined concentration, redispersibility, or dosing properties can create a stronger barrier.

Excipient claims are most valuable when they are tied to measurable product attributes, such as:

• A defined givinostat concentration
• A specific viscosity range
• Sedimentation volume
• Redispersion time
• Dose uniformity after storage
• Stability across temperature conditions
• Preservative effectiveness
• Compatibility with an oral syringe
• A defined taste-masking system

A competitor may avoid literal infringement by changing the polymer, sweetener, flavor, buffer, or preservative while preserving the same commercial concentration. This makes formulation patents less durable than compound claims unless they capture a technical result that is difficult to reproduce with alternative excipients.

How does Duvyzat’s excipient strategy support pediatric adherence?

Pediatric adherence is a central commercial issue for DMD therapies. Treatment begins in childhood, and patients may receive therapy for many years. The formulation must work for caregivers administering repeated doses at home.

Taste masking

Sucralose and flavoring address the acceptability of givinostat. A high-intensity sweetener is useful because it contributes limited volume and can provide sweetness at low concentration. The formulation must balance sweetness against bitterness, aftertaste, and the sensory effects of glycerin and the suspending polymer.

Potential improvement opportunities include:

• More effective bitterness blockers
• Ion-pairing or complexation approaches
• Taste-masked microparticles
• Lipid or polymer coatings
• Multi-flavor options for different age groups
• Reduced sweetness for patients with long-term exposure

A taste-masking system that reduces the need for sweetener or flavor can improve tolerability and may simplify global excipient compliance.

Viscosity and mouthfeel

A thick suspension can improve physical stability but may be difficult to swallow or draw through a syringe. Excessive viscosity can also increase dosing errors if the caregiver dispenses the product too quickly or if residual liquid remains in the syringe.

The commercial target is a low-to-moderate viscosity that keeps the drug uniformly dispersed while allowing rapid syringe filling and administration. This creates opportunities for polymer systems with shear-thinning behavior, improved wetting, and low residual coating on the bottle and syringe.

Dose flexibility

DMD patients grow substantially during treatment. A weight-based liquid allows clinicians to adjust the administered volume without changing dosage units. This is a major advantage over fixed-strength tablets.

The formulation must remain accurate at low and high dose volumes. A child receiving a small dose may be particularly exposed to errors from:

• Inadequate bottle shaking
• Incomplete syringe filling
• Retention in the syringe
• Foaming
• Suspended-particle settling
• Incorrect syringe graduation

A dosing system with a low dead volume and clear weight-based instructions is a meaningful commercial differentiator.

What commercial opportunities exist for Duvyzat excipients?

The opportunity is concentrated in excipient performance rather than simple commodity supply. Duvyzat is an orphan drug, so total volume may be limited relative to mass-market pediatric medicines. The product’s high clinical value and chronic use increase the value of validated formulation improvements.

1. Advanced suspending agents

Suppliers can target polymers that improve redispersion without creating excessive viscosity. The most attractive materials would provide:

• Fast hydration
• Low batch-to-batch variability
• Stable viscosity over shelf life
• Low interaction with givinostat
• Low microbial risk
• Compatibility with preservatives
• Regulatory acceptance in the United States and Europe

Cellulose derivatives, polyacrylic acid systems, xanthan-based systems, and newer structured vehicles may compete in this area. A replacement would require comparative data on sedimentation, assay uniformity, rheology, and stability.

2. Preservative systems

Sodium benzoate is established for oral liquids, but preservative performance depends on pH, concentration, packaging, and microbial challenge testing. Opportunities include lower-preservative systems, preservative combinations, or packaging that reduces contamination during repeated use.

A reformulation would need to preserve antimicrobial protection while controlling:

• Benzene formation risk under relevant conditions
• Taste impact
• Age-related exposure considerations
• Compatibility with bottle and syringe materials
• Preservative effectiveness after opening

3. Taste-masking technologies

Taste masking is one of the most commercially attractive areas because it directly affects adherence. A supplier with a platform for bitter small molecules could offer:

• Coated drug particles
• Ion-exchange resin complexes
• Lipid matrices
• Cyclodextrin complexes
• pH-dependent release systems
• Multiparticulate suspensions

The main barrier is maintaining immediate or clinically appropriate release after the formulation is swallowed. A taste-masked particle must not materially alter givinostat exposure.

4. Oral syringe and dosing-system partnerships

The Duvyzat label relies on oral syringes for dose measurement [2]. Device suppliers can compete through low-residual-volume syringes, dose-specific graduations, and designs that reduce suspension separation during filling.

Commercial opportunities include:

• Weight-band dosing syringes
• Syringes with improved barrel visibility
• Reduced dead space
• Child-resistant but caregiver-friendly systems
• Bottle adapters that limit contamination
• Connected dose-tracking systems

A proprietary device may strengthen product differentiation even when the liquid formulation is not materially changed.

5. Ready-to-use and alternate presentations

A ready-to-use suspension minimizes caregiver preparation. Other opportunities include:

• Unit-dose sachets
• Stick packs
• Smaller travel bottles
• Powder-for-reconstitution presentations
• High-concentration formulations that reduce dose volume
• Dispersible tablets for older children
• Sprinkle or multiparticulate formats

A higher-concentration liquid could reduce administration burden but would increase the importance of dose-measurement accuracy and suspension uniformity.

What is the FDA regulatory status of Duvyzat?

The FDA approved Duvyzat under the orphan-drug framework for DMD. The approval was supported by clinical data, including the Phase 3 EPIDYS study, which evaluated givinostat in ambulatory boys with DMD receiving corticosteroids [1].

The product is regulated as a prescription drug and has an FDA-approved labeling framework covering:

• Indication
• Weight-based dosing
• Laboratory monitoring
• Drug interactions
• Adverse reactions
• Storage and administration
• Handling of the oral suspension

The label includes warnings concerning platelet counts, triglycerides, QTc prolongation, gastrointestinal effects, and laboratory monitoring [2]. These safety requirements create an opportunity for formulation strategies that reduce dose variability and support consistent administration.

When does Duvyzat lose exclusivity?

Duvyzat’s exclusivity position includes orphan-drug exclusivity beginning with the March 21, 2024 approval. Orphan exclusivity generally lasts seven years for the approved indication, subject to statutory exceptions. The product may also receive new-chemical-entity exclusivity if FDA determines that givinostat qualifies under the applicable framework.

Exclusivity or protection	Timing
FDA approval	March 21, 2024
Orphan-drug exclusivity	Generally through March 21, 2031
Potential NCE exclusivity	Generally five years from approval, subject to FDA classification
Pediatric exclusivity	Possible six-month extension if awarded
Patent rights	Depend on individual patent claims and expiration dates

The end of regulatory exclusivity does not automatically permit immediate generic entry if enforceable patents remain. Conversely, expiration of a patent does not remove FDA regulatory exclusivity.

Are Paragraph IV challenges likely?

A Paragraph IV challenge is more likely after the relevant generic filing window opens and once the commercial opportunity is large enough to justify development costs. Duvyzat’s orphan population limits volume, but its chronic use and high specialty-drug pricing could support a targeted challenge.

A generic applicant would need to address:

• Reference-listed-drug product selection
• Suspension bioequivalence
• Dose uniformity
• Comparative dissolution or in vitro performance
• Container-closure compatibility
• Preservative effectiveness
• Taste and administration differences
• Listed method-of-use patents
• Any formulation patents

The main generic risk may come from a differentiated oral suspension rather than a direct copy of the excipient system.

What patent litigation and settlement risks affect Duvyzat?

Duvyzat’s litigation exposure is likely to center on the active ingredient, DMD treatment claims, dosage regimens, and formulation claims. A generic filing could trigger patent litigation under the Hatch-Waxman framework if a Paragraph IV certification is made against Orange Book-listed patents.

Potential settlement structures could include:

• Delayed generic entry
• Authorized generic arrangements
• License rights for specific jurisdictions
• Restrictions on formulation or indication
• Entry dates linked to patent expiration
• Supply or manufacturing agreements

A settlement involving a generic liquid suspension could have greater commercial impact than one involving an alternate dosage form because it would directly compete with Duvyzat’s pediatric administration model.

How strong is the Duvyzat excipient estate compared with the active-ingredient estate?

The active-ingredient estate is generally stronger when it contains valid compound claims. Excipient protection is more exposed to substitution and formulation redesign.

Estate component	Relative strength	Main vulnerability
Givinostat compound	High if unexpired and valid	Invalidity or noninfringement arguments
DMD method of use	Moderate to high	Indication and claim-scope limitations
Dose regimen	Moderate	Alternative dosing schedules
Oral suspension	Moderate	Polymer, pH, or concentration substitution
Taste-masking system	Moderate	Alternative sensory technologies
Dosing device	Low to moderate	Use of a non-infringing device
Manufacturing process	Variable	Process redesign or alternative suppliers

The commercial defense is strongest when the formulation patent covers performance characteristics that a competitor must reproduce to obtain a clinically acceptable and regulatorily comparable product.

Which companies could challenge Duvyzat commercially?

Potential challengers include generic pharmaceutical companies with oral-liquid capabilities, specialty-drug manufacturers, and companies with pediatric suspension platforms. The most credible entrants would have experience with:

• FDA abbreviated new drug applications
• Complex oral suspensions
• Orphan-drug markets
• Pediatric taste masking
• Low-volume specialty products
• Drug-device combination packaging

Large generic manufacturers may be less interested if the addressable patient population is small. A specialty generic company could have a stronger strategic fit because it can tolerate lower unit volume and focus on high-value products.

How does Duvyzat compare with competing DMD therapies?

Duvyzat differs from several DMD treatments in both mechanism and dosage form.

Product	Active ingredient	Formulation	Commercial implication
Duvyzat	Givinostat	Ready-to-use oral suspension	Flexible pediatric dosing; excipient and syringe performance are central
Emflaza	Deflazacort	Tablets and oral suspension	Established corticosteroid liquid benchmark
Prednisone	Prednisone	Tablets and liquid formulations	Lower-cost generic competition
Agamree	Vamorolone	Oral suspension	Direct competition for liquid administration and adherence
Exondys 51	Eteplirsen	Intravenous injection	Administration burden differs substantially
Elevidys	Delandistrogene moxeparvovec	Intravenous gene therapy	One-time or limited administration model

Vamorolone is the closest commercial comparator in liquid pediatric administration. Duvyzat’s excipient strategy must compete on taste, dose volume, bottle usability, storage, and caregiver burden, not only on clinical mechanism.

What geographic opportunities exist for Duvyzat excipients?

United States commercialization creates the first major market, but European and other international launches may require excipient and packaging adaptation.

Regional issues include:

• Different positive and negative excipient lists
• Pediatric safety expectations
• Country-specific flavor restrictions
• Preservative requirements
• Packaging-language requirements
• Stability zones and shipping conditions
• Local device registration
• Pharmacopoeial specifications
• Availability of qualified excipient suppliers

A global formulation based on widely accepted excipients can reduce regulatory complexity. However, taste preferences and labeling requirements may favor regional flavor variants or alternate presentations.

Key Takeaways

• Duvyzat is a weight-based givinostat oral suspension approved by the FDA in 2024 for DMD patients aged 6 years and older.
• Its excipient system supports suspension stability, taste masking, preservation, pH control, and accurate syringe dosing.
• The largest formulation opportunities are advanced suspending agents, taste-masking systems, preservative optimization, and oral dosing devices.
• Formulation patents are generally more vulnerable to design-around than compound patents, but claims tied to measurable performance may provide meaningful protection.
• Generic entry risk is constrained by the orphan population but may be supported by chronic treatment duration and specialty-drug pricing.
• Vamorolone and deflazacort suspensions provide the most relevant commercial benchmarks for pediatric liquid administration.
• Global opportunities depend on excipient acceptability, preservative rules, packaging requirements, and regional taste preferences.

FAQs About Duvyzat Excipients and Commercial Strategy

What is the active ingredient in Duvyzat?

Duvyzat contains givinostat, a histone deacetylase inhibitor used for Duchenne muscular dystrophy.

Is Duvyzat a solution or a suspension?

Duvyzat is an oral suspension. The product must be shaken and administered with the supplied oral syringe according to the FDA labeling.

Why does Duvyzat need a suspending agent?

The suspending system helps keep givinostat particles distributed throughout the liquid so that measured doses remain consistent after the bottle is shaken.

Can Duvyzat be reformulated as a tablet?

A tablet or capsule could be developed for older patients, but it would need to preserve dose flexibility, exposure, stability, and regulatory equivalence. It would not automatically replace the pediatric advantages of the liquid suspension.

What is the main commercial risk for a Duvyzat reformulation?

The main risk is disrupting dose uniformity, taste, preservative protection, or bioavailability while attempting to reduce excipient burden or administration volume.

References

1. U.S. Food and Drug Administration. (2024, March 21). FDA approves drug for Duchenne muscular dystrophy. https://www.fda.gov/news-events/press-announcements/fda-approves-drug-duchenne-muscular-dystrophy

2. Italfarmaco S.p.A. (2024). Duvyzat (givinostat) oral suspension, prescribing information. U.S. Food and Drug Administration.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm